Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice

Human Molecular Genetics

Volumn 23, Issue 17, 2014, Pages 4543-4558

  Saito, Fumiaki ^a   Kanagawa, Motoi ^b   Ikeda, Miki ^a   Hagiwara, Hiroki ^a,c   Masaki, Toshihiro ^a,c   Ohkuma, Hidehiko ^a   Katanosaka, Yuki ^d   Shimizu, Teruo ^e   Sonoo, Masahiro ^a   Toda, Tatsushi ^b   Matsumura, Kiichiro ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY OF SCIENCE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FUKUTIN; LAMININ ALPHA2; LIKE ACETYLGLUCOSAMINYLTRANSFERASE; SOMATOMEDIN C; TRANSFERASE; UNCLASSIFIED DRUG; DYSTROGLYCAN; FCMD PROTEIN, MOUSE; LARGE PROTEIN, MOUSE; N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; KNOCKOUT MOUSE; MORPHOMETRICS; MOUSE; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; CELL FUSION; CELL LINE; GLYCOSYLATION; HUMAN; METABOLISM; MYOBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; REGENERATION; SKELETAL MUSCLE;

ANIMALS; CELL FUSION; CELL LINE; DOWN-REGULATION; DYSTROGLYCANS; GLYCOSYLATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, TRANSGENIC; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOBLASTS; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHENOTYPE; PROTEINS; REGENERATION; TRANSFECTION;

EID: 84905668632     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu168     Document Type: Article

References (66)

1. Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., Sernett, S.W. and Campbell, K.P. (1992) Primary structure of dystrophinassociated glycoproteins linking dystrophin to the extracellular matrix. Nature, 355, 696-702.
2. Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K.P. and Südhof, T.C. (2001) A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell Biol., 154, 435-445.
3. Sato, S., Omori, Y., Katoh, K., Kondo, M., Kanagawa, M., Miyata, K., Funabiki, K., Koyasu, T., Kajimura, N., Miyoshim, T. et al. (2008) Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat. Neurosci., 11, 923-931.
4. Ervasti, J.M. and Campbell, K.P. (1993) A role for the dystrophin- glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell. Biol., 122, 809-823.
5. Jung, D., Yang, B., Meyer, J., Chamberlain, J.S. and Campbell, K.P. (1995) Identification and characterization of the dystrophin anchoring site on β-dystroglycan. J. Biol. Chem., 270, 27305-27310.
6. Kanagawa, M., Saito, F., Kunz, S., Yoshida-Moriguchi, T., Barresi, R., Kobayashi, Y.M., Muschler, J., Dumanski, J.P., Michele, D.E., Oldstone, M.B. et al. (2004) Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell, 117, 953-964.
7. Saito, F., Saito-Arai, Y., Nakamura, A., Shimizu, T. and Matsumura, K. (2008) Processing and secretion of the N-terminal domain of α-dystroglycan in cell culture media. FEBS Lett., 582, 439-444.
8. Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S., Kanazawa, I., Kobata, A. and Endo, T. (1997) Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve α-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of α-dystroglycan with laminin. J. Biol. Chem., 272, 2156-2162.
9. Yoshida-Moriguchi, T., Yu, L., Stalnaker, S.H., Davis, S., Kunz, S., Madson, M., Oldstone, M.B., Schachter, H., Wells, L. and Campbell, K.P. (2010) O-mannosyl phosphorylation of α-dystroglycan is required for laminin binding. Science, 327, 88-92.
10. Inamori, K., Yoshida-Moriguchi, T., Hara, Y., Anderson, M.E., Yu, L. and Campbell, K.P. (2012) Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science, 335, 93-96.
11. Yoshida-Moriguchi, T., Willer, T., Anderson, M.E., Venzke, D., Whyte, T., Muntoni, F., Lee, H., Nelson, S.F., Yu, L. and Campbell, K.P. (2013) SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science, 341, 896-899.
12. Michele, D.E., Barresi, R., Kanagawa, M., Saito, F., Cohn, R.D., Satz, J.S., Dollar, J., Nishino, I., Kelley, R.I., Somer, H. et al. (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature, 418, 417-422.
13. Brown, S.C. and Winder, S.J. (2011)Dystroglycan and dystroglycanopathies: report of the 187th ENMC Workshop 11-13 November 2011, Naarden, The Netherlands. Neuromuscul. Disord., 22, 659-668.
14. Kobayashi, K., Nakahori, Y., Miyake, M., Matsumura, K., Kondo-Iida, E., Nomura, Y., Segawa, M., Yoshioka, M., Saito, K., Osawa, M. et al. (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature, 394, 388-392.
15. Taniguchi-Ikeda, M., Kobayashi, K., Kanagawa, M., Yu, C.C., Mori, K., Oda, T., Kuga, A., Kurahashi, H., Akman, H.O., DiMauro, S. et al. (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature, 478, 127-131.
16. Beltran-Valero, D.B., Currier, S., Steinbrecher, A., Celli, J., van Beusekom, E., van der, Z.B., Kayserili, H., Merlini, L., Chitayat, D., Dobyns, W.B. et al. (2002) Mutations in the O-mannosyltransferase genePOMT1give rise to the severe neuronal migration disorderWalker-Warburg syndrome. Am. J.Hum. Genet., 71, 1033-1043.
17. Manya, H., Chiba, A., Yoshida, A., Wang, X., Chiba, Y., Jigami, Y., Margolis, R.U. and Endo, T. (2004) Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl. Acad. Sci. USA, 101, 500-505.
18. van Reeuwijk, J., Janssen, M., van den, E.C., Beltran-Valero de, B.D., Sabatelli, P., Merlini, L., Boon, M., Scheffer, H., Brockington, M., Muntoni, F. et al. (2005) POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet., 42, 907-912.
19. Yoshida, A., Kobayashi, K., Manya, H., Taniguchi, K., Kano, H., Mizuno, M., Inazu, T., Mitsuhashi, H., Takahashi, S., Takeuchi, M. et al. (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell, 1, 717-724.
20. Longman, C., Brockington, M., Torelli, S., Jimenez-Mallebrera, C., Kennedy, C., Khalil, N., Feng, L., Saran, R.K., Voit, T., Merlini, L. et al. (2003) Mutations in the humanLARGEgene causeMDC1D,a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan. Hum. Mol. Genet., 12, 2853-2861.
21. Jae, L.T., Raaben, M., Riemersma, M., van Beusekom, E., Blomen, V.A., Velds, A., Kerkhoven, R.M., Carette, J.E., Topaloglu, H., Meinecke, P. et al. (2013) Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science, 340, 479-483.
22. Manzini, M.C., Tambunan, D.E., Hill, R.S., Yu, T.W., Maynard, T.M., Heinzen, E.L., Shianna, K.V., Stevens, C.R., Partlow, J.N., Barry, B.J. et al. (2012) Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am. J. Hum. Genet., 91, 541-547.
23. Stevens, E., Carss, K.J., Cirak, S., Foley, A.R., Torelli, S., Willer, T., Tambunan, D.E., Yau, S., Brodd, L., Sewry, C.A. et al. (2013) Mutations in B3GALNT2cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. Am. J. Hum. Genet., 92, 354-365.
24. Lefeber, D.J., de Brouwer, A.P., Morava, E., Riemersma, M., Schuurs-Hoeijmakers, J.H., Absmanner, B., Verrijp, K., van den Akker, W.M., Huijben, K., Steenbergen, G. et al. (2011) Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS. Genet., 7, e1002427.
25. Carss, K.J., Stevens, E., Foley, A.R., Cirak, S., Riemersma, M., Torelli, S., Hoischen, A., Willer, T., van, S.M., Moore, S.A. et al. (2013) Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. Am. J. Hum. Genet., 93, 29-41.
26. Yang, A.C., Ng, B.G., Moore, S.A., Rush, J., Waechter, C.J., Raymond, K.M., Willer, T., Campbell, K.P., Freeze, H.H. and Mehta, L. (2013) Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. Mol. Genet. Metab., 10, 345-351.
27. Barone, R., Aiello, C., Race, V., Morava, E., Foulquier, F., Riemersma, M., Passarelli, C., Concolino, D., Carella, M., Santorelli, F. et al. (2012) DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann. Neurol., 72, 550-558.
28. Lefeber, D.J., Schonberger, J., Morava, E., Guillard, M., Huyben, K.M., Verrijp, K., Grafakou, O., Evangeliou, A., Preijers, F.W., Manta, P. et al. (2009) Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am. J. Hum. Genet., 85, 76-86.
29. Brockington, M., Blake, D.J., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., Ponting, C.P., Estournet, B., Romero, N.B., Mercuri, E. et al. (2001) Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin a2 deficiency and abnormal glycosylation of α-dystroglycan. Am. J. Hum. Genet., 69, 1198-1209.
30. Buysse, K., Riemersma, M., Powell, G., van, R.J., Chitayat, D., Roscioli, T., Kamsteeg, E.J., van den Elzen, C., van, B.E., Blaser, S. et al. (2013) Missense mutations in b-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum. Mol. Genet., 22, 1746-1754.
31. Willer, T., Lee, H., Lommel, M., Yoshida-Moriguchi, T., de Bernabe, D.B., Venzke, D., Cirak, S., Schachter, H., Vajsar, J., Voit, T. et al. (2012) ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat. Genet., 44, 575-580.
32. Roscioli, T., Kamsteeg, E.J., Buysse, K., Maystadt, I., van Reeuwijk, J., van den Elzen, C., van Beusekom, E., Riemersma, M., Pfundt, R., Vissers, L.E. et al. (2012) Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan. Nat. Genet., 44, 581-585.
33. Vuillaumier-Barrot, S., Bouchet-Seraphin, C., Chelbi, M., Devisme, L., Quentin, S., Gazal, S., Laquerriere, A., Fallet-Bianco, C., Loget, P., Odent, S. et al. (2012) Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am. J. Hum. Genet., 91, 1135-1143.
34. Hara, Y., Balci-Hayta, B., Yoshida-Moriguchi, T., Kanagawa, M., Beltrán-Valero de Bernabé, D., Gündeşli, H., Willer, T., Satz, J.S., Crawford, R.W., Burden, S.J. et al. (2011) A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med., 364, 939-946.
35. Muntoni, F. and Voit, T. (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul. Disord., 14, 635-649.
36. Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F., Weissenbach, J., Tomé, F.M., Schwartz, K., Fardeau, M., Tryggvason, K. et al. (1995) Mutations in the laminin a2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat. Genet., 11, 216-218.
37. Geranmayeh, F., Clement, E., Feng, L.H., Sewry, C., Pagan, J., Mein, R., Abbs, S., Brueton, L., Childs, A.M., Jungbluth, H. et al. (2010) Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul. Disord., 20, 241-250.
38. Barresi, R., Michele, D.E., Kanagawa, M., Harper, H.A., Dovico, S.A., Satz, J.S., Moore, S.A., Zhang, W., Schachter, H., Dumanski, J.P. et al. (2004) LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med., 10, 696-703.
39. Sunada, Y., Bernier, S.M., Utani, A., Yamada, Y. and Campbell, K.P. (1995) Identification of a novel mutant transcript of laminin a2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum. Mol. Genet., 4, 1055-1061.
40. Kanagawa, M., Yu, C.C., Ito, C., Fukada, S., Hozoji-Inada, M., Chiyo, T., Kuga, A., Matsuo, M., Sato, K., Yamaguchi, M. et al. (2013) Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Hum. Mol. Genet., 22, 3003-3015.
41. Goddeeris, M.M., Wu, B., Venzke, D., Yoshida-Moriguchi, T., Saito, F., Matsumura, K., Moore, S.A. and Campbell, K.P. (2013)LARGEglycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy. Nature, 503, 136-140.
42. Colognato, H. and Yurchenco, P.D. (1999) The laminin a2 expressed by dystrophic dy(2J) mice is defective in its ability to form polymers. Curr. Biol., 9, 1327-1330.
43. Straub, V., Rafael, J.A., Chamberlain, J.S. and Campbell, K.P. (1997) Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell. Biol., 139, 375-385.
44. Irintchev, A., Zeschnigk, M., Starzinski-Powitz, A. and Wernig, A. (1994) Expression pattern of M-cadherin in normal, denervated, and regenerating mouse muscles. Dev. Dyn., 199, 326-337.
45. Kottlors, M. and Kirschner, J. (2010) Elevated satellite cell number in Duchenne muscular dystrophy. Cell Tissue Res., 340, 541-548.
46. Brockington, M., Torelli, S., Prandini, P., Boito, C., Dolatshad, N.F., Longman, C., Brown, S.C. and Muntoni, F. (2005) Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy. Hum. Mol. Genet., 14, 657-665.
47. Clemmons, D.R. (2009) Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol. Metab., 20, 349-356.
48. Brockington, M., Torelli, S., Sharp, P.S., Liu, K., Cirak, S., Brown, S.C., Wells, D.J. and Muntoni, F. (2010) Transgenic overexpression of LARGE induces α-dystroglycan hyperglycosylation in skeletal and cardiac muscle. PLoS One, 5, e14434.
49. Gumerson, J.D., Davis, C.S., Kabaeva, Z.T., Hayes, J.M., Brooks, S.V. and Michele, D.E. (2013) Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGEmyd mice. Hum. Mol. Genet., 22, 757-768.
50. Whitmore, C., Fernandez-Fuente, M., Booler, H., Parr, C., Kavishwar, M., Ashraf, A., Lacey, E., Kim, J., Terry, R., Ackroyd, M.R. et al. (2014) The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Hum. Mol. Genet., 23, 1842-1855.
51. Relaix, F. and Zammit, P.S. (2012) Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development, 139, 2845-2856.
52. Ciciliot, S. and Schiaffino, S. (2010) Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr. Pharm. Des., 16, 906-914.
53. Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E.R., Sweeney, H.L. and Rosenthal, N. (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet., 27, 195-200.
54. Barton, E.R., Morris, L., Musaro, A., Rosenthal, N. and Sweeney, H.L. (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell. Biol., 157, 137-148.
55. Kumar, A., Yamauchi, J., Girgenrath, T. and Girgenrath, M. (2011) Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum. Mol. Genet., 20, 2333-2343.
56. Coolican, S.A., Samuel, D.S., Ewton, D.Z., McWade, F.J. and Florini, J.R. (1997) The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem., 272, 6653-6662.
57. Tureckova, J., Wilson, E.M., Cappalonga, J.L. and Rotwein, P. (2001) Insulin-like growth factor-mediated muscle differentiation: collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J. Biol. Chem., 276, 39264-39270.
58. James, M., Nuttall, A., Ilsley, J.L., Ottersbach, K., Tinsley, J.M., Sudol, M. and Winder, S.J. (2000) Adhesion-dependent tyrosine phosphorylation of β-dystroglycan regulates its interaction with utrophin. J. Cell. Sci., 113, 1717-1726.
59. Ilsley, J.L., Sudol, M. and Winder, S.J. (2001) The interaction of dystrophin with β-dystroglycan is regulated by tyrosine phosphorylation. Cell Signal., 13, 625-632.
60. Sotgia, F., Lee, H., Bedford, M.T., Petrucci, T., Sudol, M. and Lisanti, M.P. (2001) Tyrosine phosphorylation of β-dystroglycan at itsWWdomain bindingmotif, PPxY, recruits SH2 domain containing proteins. Biochemistry, 40, 14585-14592.
61. Langenbach, K.J. and Rando, T.A. (2002) Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve., 26, 644-653.
62. Zhou, Y., Jiang, D., Thomason, D.B. and Jarrett, H.W. (2007) Laminin-induced activation of Rac1 and JNKp46 is initiated by Src family kinases and mimics the effects of skeletal muscle contraction. Biochemistry, 46, 14907-14916.
63. Zhang, P. and Hu, H. (2012) Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase. Glycobiology, 22, 235-247.
64. Bao, X., Kobayashi, M., Hatakeyama, S., Angata, K., Gullberg, D., Nakayama, J., Fukuda, M.N. and Fukuda, M. (2009) Tumor suppressor function of laminin-binding α-dystroglycan requires a distinct b3-N-acetylglucosaminyltransferase. Proc. Natl. Acad. Sci. USA, 106, 12109-12114.
65. Yu, M., He, Y., Wang, K., Zhang, P., Zhang, S. and Hu, H. (2013) Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum. Gene. Ther., 24, 317-330.
66. Saito, F., Masaki, T., Saito, Y., Nakamura, A., Takeda, S., Shimizu, T., Toda, T. and Matsumura, K. (2007) Defective peripheral nerve myelination and neuromuscular junction formation in fukutin-deficient chimeric mice. J. Neurochem., 101, 1712-1722.